| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/11/2001 | EP1089757A1 Hla binding peptides and their uses |
| 04/11/2001 | EP1089756A1 CORRELATIVE PROTECTION USING OspA ANTIBODY TITERS |
| 04/11/2001 | EP1089751A1 Adjuvant therapy |
| 04/11/2001 | CN1291235A Vaccines immunotherapeutics and method for using the same |
| 04/11/2001 | CN1291233A Human complement (3-degrading proteinase from i (streptococcus pheumoniae) |
| 04/11/2001 | CN1291231A Human telomerase catalytic subunit |
| 04/11/2001 | CN1291107A Skin cave compositions |
| 04/11/2001 | CN1291106A Novel preventives/remedies for immunopathy |
| 04/11/2001 | CN1291105A Hapten-modified tumor cell membranes and preparation and method for using it |
| 04/11/2001 | CN1290749A Charcot-leyden crystal IB and its coding sequence and producing method and use |
| 04/11/2001 | CN1290748A New human protein and its coding sequence, and producing method and use |
| 04/11/2001 | CN1290747A New human metal thioalbumen and its coding sequence |
| 04/10/2001 | US6214984 Nucleic acid coding for a linear heavy chain fragment including repeating variable and constant domains; recombinant production |
| 04/10/2001 | US6214981 Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof |
| 04/10/2001 | US6214973 Antibody light chain having variable region of defined amino acid sequence and human constant region; antitumor agents; anticarcinogenic agents; diagnosis |
| 04/10/2001 | US6214971 Compounds and methods for the diagnosis and treatment of Babesia microti infection |
| 04/10/2001 | US6214970 Hepatitis E virus antigens and uses therefor |
| 04/10/2001 | US6214614 Cell cycle regulated repressor and DNA element |
| 04/10/2001 | US6214602 Host cells for expression of clostridial toxins and proteins |
| 04/10/2001 | US6214600 Polypeptide of defined amino acid sequence; treatment of alzheimer's disease, stroke, musculoskeletal disease, heart disease, kidney disease; anticarcinogenic/antiinflammatory agents; antiarthritic agents; diagnosis |
| 04/10/2001 | US6214595 Enzymatic polypeptide for utilization in screening bactericides; wound healing agents; for prevent of bacterial wound infections |
| 04/10/2001 | US6214583 HCV genomic sequences for diagnostics and therapeutics |
| 04/10/2001 | US6214579 Flea leucine aminopeptidase nucleic acid molecules and uses thereof |
| 04/10/2001 | US6214562 Transcriptionally regualted G protein-coupled receptor |
| 04/10/2001 | US6214543 DNA molecule encoding for cellular uptake of Mycobacterium tuberculosis and uses thereof |
| 04/10/2001 | US6214539 Synthetic antigen the detection of aids-related disease |
| 04/10/2001 | US6214537 Amino acid sequences for the detection of preferential viral diseases |
| 04/10/2001 | US6214388 Immunoliposomes that optimize internalization into target cells |
| 04/10/2001 | US6214367 For treating parasitic diseases and preventing bacterial and viral diseases in warm-blooded animals; stability |
| 04/10/2001 | US6214356 Administering to the mammal a preparation comprising a portion of the amino acid sequence of mature adenylate cyclase of a second bordetella species; respiratory diseases, whooping cough |
| 04/10/2001 | US6214355 DbpA compositions |
| 04/10/2001 | US6214354 Immunizing a person older than fifty who has had varicella or who has had a live varicella vaccine with immunologically effective amount of attenuated varicella zoster virus oka strain, where amount is at least 1,000 plaque forming units |
| 04/10/2001 | US6214353 Malaria recombinant poxvirus vaccine |
| 04/10/2001 | US6214348 Administering to the mammal a polypeptide comprising seq id no:2 in an amount sufficient to induce an immunological response to produce antibodies to seq id no:2 |
| 04/10/2001 | US6214347 Multideterminant peptides that elicit helper T-lymphocyte, cytotoxic T lymphocyte and neutralizing antibody responses against HIV-1 |
| 04/10/2001 | US6214346 Bactericides |
| 04/10/2001 | US6214345 Lysosomal enzyme-cleavable antitumor drug conjugates |
| 04/10/2001 | US6214342 Method for increasing mean survival times of transplants with LFA-1-specific antibodies |
| 04/10/2001 | US6214341 Percutaneously administering to patient an effective amount of human clostridium difficile toxin-neutralizing polyclonal immune globulin obtained from a human subject immunized with a clostridium difficile toxin or toxoid |
| 04/10/2001 | CA2200855C Radioactive phosphorous labeling of proteins for targeted radiotherapy |
| 04/10/2001 | CA2191858C Thiolation of proteins for radionuclide-based radioimmunodetection and radioimmunotherapy |
| 04/10/2001 | CA2190344C Quillaja saponin adjuvant and vaccine formulation containing same |
| 04/10/2001 | CA2163151C Humanized and chimeric monoclonal antibodies that recognized epidermal growth factor receptor (egf-r). use diagnostic and therapeutic |
| 04/10/2001 | CA2152075C Vaccination with peptide of mhc class ii molecules for treatment of autoimmune disease |
| 04/10/2001 | CA2130436C Cloning and expression of humanized monoclonal antibodies against human interleukin-4 |
| 04/10/2001 | CA2081150C Use of antibody-containing preparations for immunosuppression |
| 04/10/2001 | CA2074089C Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor |
| 04/10/2001 | CA2067233C Fibronectin binding peptide |
| 04/05/2001 | WO2001023604A2 Highly conserved genes and their use to generate probes and primers for detection of microorganisms |
| 04/05/2001 | WO2001023599A1 Streptococcus pneumoniae ykqc |
| 04/05/2001 | WO2001023597A2 Cell lines and constructs useful in production of e1-deleted adenoviruses in absence of replication competent adenovirus |
| 04/05/2001 | WO2001023587A2 Serine protease |
| 04/05/2001 | WO2001023572A2 Polynucleotides and polypeptides encoded thereby |
| 04/05/2001 | WO2001023560A2 Isolated peptides which bind to mhc class ii molecules, and uses thereof |
| 04/05/2001 | WO2001023554A1 The prv-1 gene and use thereof |
| 04/05/2001 | WO2001023550A2 Pca3 messenger rna species in benign and malignant prostate tissues |
| 04/05/2001 | WO2001023546A1 37 human secreted proteins |
| 04/05/2001 | WO2001023540A2 P-glycoproteins and uses thereof |
| 04/05/2001 | WO2001023537A1 Process for enhancing electric field-mediated delivery of biological materials into cells |
| 04/05/2001 | WO2001023422A1 Vaccine |
| 04/05/2001 | WO2001023421A2 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| 04/05/2001 | WO2001023417A2 Human tumor-associated lak-4p related polynucleotides and polypeptides and their uses |
| 04/05/2001 | WO2001023416A2 Immunogenic polypeptide derived from moraxella catarrhalis and uses thereof |
| 04/05/2001 | WO2001023414A2 Immunologically significant herpes simplex virus antigens |
| 04/05/2001 | WO2001023001A2 Rapid peg-modification |
| 04/05/2001 | WO2001022995A1 A method for preparing conjugates between an antigen and mucosal binding component |
| 04/05/2001 | WO2001022994A2 Vaccines against neisseria infection |
| 04/05/2001 | WO2001022993A2 MUCOSAL DTPa VACCINES |
| 04/05/2001 | WO2001022992A2 Influenza vaccine |
| 04/05/2001 | WO2001022987A1 Trail: an inhibitor of autoimmune inflammation and cell cycle progression |
| 04/05/2001 | WO2001022972A2 Immunostimulatory nucleic acids |
| 04/05/2001 | WO2001022922A2 Engineering antibodies that bind irreversibly |
| 04/05/2001 | WO2001022916A2 Novel hev antigenic peptide and methods |
| 04/05/2001 | WO2001006015A8 NOVEL GLYCOSYL SULFOTRANSFERASES GST-4α, GST-4β, AND GST-6 |
| 04/05/2001 | WO2000078787A8 ISOLATED GENES FROM VIRULENT GROUP B $i(STREPTOCOCCUS AGALACTIAE) |
| 04/05/2001 | WO2000073450A3 Cytoskeleton-associated proteins |
| 04/05/2001 | WO2000072023A3 Diagnosis and treatment of atherosclerosis and coronary heart disease |
| 04/05/2001 | WO2000071573A3 Immunogenic peptides derived from mage and the use thereof |
| 04/05/2001 | WO2000069455A3 Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus |
| 04/05/2001 | WO2000067788A3 Use of soluble costimulatory molecules to enhance immune responses |
| 04/05/2001 | WO2000066143A8 Secreted proteins of mycobacterium tuberculosis and their use as vaccines and diagnostic reagents |
| 04/05/2001 | WO2000064474A8 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit |
| 04/05/2001 | WO2000030668A9 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration |
| 04/05/2001 | WO2000009120A8 New use of taxoid derivatives |
| 04/05/2001 | US20010000176 Overcoming maternal immunity interference to a vaccine in a mammalian infant under one year of age inducing a protective immune by administering a transcribable polynucleotide sequence encoding an antigen of a pathogenic organism |
| 04/05/2001 | US20010000144 Symptomatic relief of allergic reactions |
| 04/05/2001 | DE19947010A1 Das Gen PRV-1 und dessen Verwendung The PRV-1 gene and its use |
| 04/05/2001 | CA2811455A1 Highly conserved genes and their use to generate species-specific, genus-specific, family-specific, group-specific and universal nucleic acid probes and amplification primers to rapidly detect and identify algal, archaeal, bacterial, fungal and parasitical microorganisms from clinical specimens for diagnosis |
| 04/05/2001 | CA2616210A1 Influenza vaccine compositions |
| 04/05/2001 | CA2390716A1 Process for enhancing electric field-mediated delivery of biological materials into cells |
| 04/05/2001 | CA2388461A1 Highly conserved genes and their use to generate probes and primers for the detection of microorganisms |
| 04/05/2001 | CA2388055A1 Immunostimulatory nucleic acids |
| 04/05/2001 | CA2387702A1 The prv-1 gene and use thereof |
| 04/05/2001 | CA2386346A1 Novel polynucleotides and polypeptides encoded thereby |
| 04/05/2001 | CA2386077A1 Immunogenic polypeptide derived from moraxella catarrhalis and uses thereof |
| 04/05/2001 | CA2386032A1 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| 04/05/2001 | CA2386028A1 Human tumor-associated lak-4p related polynucleotides and polypeptides and their uses |
| 04/05/2001 | CA2386025A1 Vaccine against neisseria infection |
| 04/05/2001 | CA2386014A1 Influenza vaccine |
| 04/05/2001 | CA2386002A1 Trail: an inhibitor of autoimmune inflammation and cell cycle progression |